Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study

Phase 1

Completed

• Conditions: Non-infectious, Non-necrotizing Anterior Scleritis
• Interventions: Drug: Dexamethasone Phosphate Ophthalmic Solution (EGP-437); Drug: Dexamethasone phosphate ophthalmic solution

• Registration Number: NCT01059955
• Lead Sponsor: John Kempen

Brief Summary

This is an initial clinical trial evaluating whether different doses of iontophoresis for delivery of dexamethasone phosphate can be tolerated by eyes of patients with non-infections, non-necrotizing scleritis. A secondary goal is to get preliminary information about whether the treatment is likely to be an effective treatment for scleritis. If the results are favorable, further trials evaluating the treatment may be pursued.

Funding sources: FDA OOPD, Eyegate Pharmaceuticals, Inc.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-01-28
• Study First Submitted QC: 2010-01-28
• Study First Posted: 2010-02-01
• Study Start: 2012-01
• Primary Completion: 2014-02
• Study Completion: 2014-02
• Status Verified: 2016-04
• Last Update Submitted: 2016-04-20
• Last Update Posted: 2016-04-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

1. Male or female age at least 18 years
2. A diagnosis of active non-infectious, non-necrotizing anterior scleritis (nodular or diffuse is acceptable)
3. Not planning to undergo elective ocular surgery during the study
4. Provide written informed consent
5. Be able and willing to follow instructions, return for all study visits, and willing to comply with all study-related instructions
6. If female and of childbearing potential; submit a urine sample and have a negative pregnancy test at Visit 1; agree to use an acceptable method of contraception during the study. A woman is considered of childbearing potential unless she is surgically sterile (hysterectomy or tubal ligation) or is post-menopausal (has not had a menstrual cycle for >2 years or has laboratory evidence of a post-menopausal state). Acceptable methods of contraception include: spermicide with barrier, hormonal contraception, IUD, or surgical sterilization of partner. Complete abstinence throughout the study period also is acceptable.

Exclusion Criteria

1. Contraindications to the use of the test articles
2. Known allergy or sensitivity to any medication used in this study, including the study medication or its components (e.g., corticosteroids)
3. For patients not taking systemic corticosteroids or immunosuppressants, any condition constituting conferring a likelihood that systemic corticosteroids or immunosuppressants would need to be started during the 56-day study period
4. For patients already taking systemic corticosteroids and/or immunosuppressants, any condition conferring a likelihood that systemic corticosteroid or immunosuppressant dosage would need to be changed during the 56-day study period
5. Intraocular pressure high enough that intraocular pressure-lowering medications are likely to be needed (≥25 mmHg or IOP>target pressure for patients with glaucoma); and/or more than two ocular anti-hypertensive medications (prior IOP-lowering surgery is acceptable; combinations of two agents such as Cosopt or Combigan are considered two medications)
6. Glaucoma sufficiently advanced that an intraocular pressure spike would potentially put the patient at substantial risk of vision loss, per the clinician-investigator's judgment.
7. Cancer
8. Subject is planning to undergo elective surgery during the study period
9. Any active ocular infections (bacterial, viral, or fungal), active ocular inflammation other than scleritis (i.e., follicular conjunctivitis, iritis), or preauricular lymphadenopathy
10. History or diagnosis of ocular herpes or corneal lesion of suspected herpetic origin
11. Severe eyelid or ocular surface lesions impeding application of the iontophoresis applicator
12. Severe / serious ocular pathology or medical condition which may preclude study completion
13. Any condition conferring a likelihood that topical ophthalmic medications in use at baseline would need to be changed during the 56-day study period.
14. History of Stevens-Johnson Syndrome or mucous membrane pemphigoid
15. Unwilling to discontinue use of contact lenses for the duration of the study
16. Any open wounds / skin disease on the forehead where the iontophoresis return electrode will be applied
17. Pacemakers and/or any other electrical sensitive support system
18. Any significant illness or condition that could, in the investigator's or sub-investigator's opinion, be expected to interfere with the study parameters or study conduct; or put the subject at significant risk
19. Be currently pregnant, nursing, or planning a pregnancy; or woman who has a positive pregnancy test
20. Participation in an investigational drug or device study within 30 days of entering the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Active treatment at day 0 and day 7	Dexamethasone Phosphate Ophthalmic Solution (EGP-437)	Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and one at Day 7. The three iontophoresis doses are: 1. Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA 2. Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA 3. Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA
Active Treatment at Day 0, Sham Treatment at Day 7	Dexamethasone phosphate ophthalmic solution	Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and a sham treatment Day 7. The three iontophoresis doses are: 1. Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA 2. Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA 3. Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA

Primary Outcome Measures

Name	Time	Method
Dose-limiting toxicity	56 days

Secondary Outcome Measures

Name	Time	Method
Improvement on scleritis scale score	56 days

Trial Locations

Locations (6)

University of California, San Francisco; 🇺🇸 San Francisco, California, United States

Oregon Health & Sciences University; 🇺🇸 Portland, Oregon, United States

University of Miami; 🇺🇸 Miami, Florida, United States

Wilmer Eye Institute/Johns Hopkins University; 🇺🇸 Baltimore, Maryland, United States

Scheie Eye Institute/University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

Montefiore Medical Center; 🇺🇸 Bronx, New York, United States